We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




AI Predicts Kidney Stone Composition From Routine Urine Tests

By LabMedica International staff writers
Posted on 16 Nov 2026

Kidney stones are a common and painful condition, affecting approximately one in 11 Americans, with lifetime recurrence rates of 60% to 80%. More...

Identifying stone composition is important for guiding treatment and preventing recurrence, but stones are not always available for analysis. To address this diagnostic challenge, researchers have developed an AI-based approach that uses routine urine test results to predict kidney stone composition.

Researchers at Mayo Clinic developed and evaluated an artificial intelligence (AI) model to predict kidney stone composition using standard 24-hour urine test results. These tests measure substances associated with kidney stone formation and help identify individual risk factors. By analyzing multiple urine measurements together, the AI model identifies patterns associated with different stone types, providing additional information to complement conventional laboratory findings.

The model was developed using data from more than 13,000 patients, including age, sex, and 24-hour urine measurements, and subsequently evaluated in an independent group of 1,653 patients. It correctly predicted kidney stone composition in 73% of cases, compared with 33% using conventional urine-based calculations alone. The model also outperformed the traditional approach across different age and sex groups. The findings were published in Mayo Clinic Proceedings on November 11, 2026.

The approach could be particularly useful when direct stone analysis is unavailable, such as when patients do not collect passed stones or specimens cannot be obtained after surgery. In these cases, clinicians typically rely on clinical information and laboratory results to estimate stone composition. By improving these predictions, the AI model could help distinguish among common stone types, including calcium oxalate, calcium phosphate, and uric acid, potentially supporting more targeted treatment and recurrence prevention strategies.

“Many patients never have a kidney stone available for analysis, so doctors are often working with an incomplete picture. Our findings show that AI may help us get more clinically useful information from a test that is already part of kidney stone care. For patients, that could mean more informed treatment decisions. For laboratories and health care systems, it highlights how existing laboratory test data can be used in new ways to support clinical care,” said Patrick Day, senior author of the study and a principal developer in Mayo Clinic's Department of Laboratory Medicine and Pathology. 

Related Links
Mayo Clinic'


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Immunofluorescence Analyzer
IFA System
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image Credit: iStock

AMP 2026 Underscores Molecular Testing’s Role in Precision Medicine for Women’s Health

Advances in molecular diagnostics are creating new opportunities to improve the detection of sexually transmitted infections, identify antibiotic resistance, and assess cancer recurrence risk in women.... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Graphical Abstract (Matthew A Butzler, Jennifer L Reed, Alaina M Olson, et al. Development of a Rapid Automated Point-of-Care Test for Mycobacterium tuberculosis Detection from Tongue Swabs and Sputum Specimens on the DASH® Rapid PCR System, Open Forum Infectious Diseases, 2026; https://doi.org/10.1093/ofid/ofag706)

Point-of-Care Test Detects Tuberculosis from Tongue Swab and Sputum

Tuberculosis remains a major infectious disease challenge, particularly in regions with limited access to diagnostic testing and treatment. Diagnosis can be time-consuming, and collecting sputum samples... Read more

Pathology

view channel
Image Credit: Adobe Stock

New Training Approach Helps AI Distinguish Neighboring Cells in Tissue

Artificial intelligence (AI) can assist with identifying cells in digital pathology images, but densely packed tissue remains difficult to analyze. Neighboring cells may be merged, counted twice, or missed,... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.